Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Overview of attention for article published in Advances in Therapy, February 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

policy: 1 policy source

twitter: 5 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 51 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

brexucabtagene autoleucel

Cited by Canadian Agency for Drugs and Technologies in Health on 08 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.